Fig. S3.
Effect of GHRH agonist MR-409 on survival and blood glucose levels of NOD/SCID mice. (A) Cumulative survival of the diabetic animals in control (C, ●) and MR-409-treated group (T, ○). (B) Blood glucose (average ± SEM) of the diabetic mice treated by either control (C, ●) or MR-409 (T, ○). Animals in group T received 10 μg of MR-409 per day s.c. from day 0 to day 21.